glp 1 hims and hers & swings to a loss in Q1 amid shift in GLP-1 strategy Hims & Hers GLP-1 pill

FEATURING Kevin Pantalone 2,136 views December 3, 2017 5 Cardiometabolic Health Congress (CMHC) CVOT Trials for Type 2 Diabetes Treatment FEATURING Robert Eckel 873 views May 7, 2018 5 ASPC 2018 Congress on CVD Prevention SESSION 3 - Cardiometabolic Discussion 26 views August 10, 2018 ASPC 2018 Congress on CVD Prevention Comprehensive Approach to Lowering CVD Risk in Diabetics FEATURING Yehuda Handelsman 781 views August 10, 2018 6 ASPC 2018 Congress on CVD Prevention Role of SGLT2/GLP1 Agents in a Preventive Cardiologists Practice, a Seminal Transition in DM Management FEATURING Mikhail Kosiborod 982 views August 10, 2018 3 UC Davis Health Diabetes and Endocrinology Symposium Goals of Diabetes Treatment and Considerations in Selecting Diabetes Medications FEATURING John Yoon 285 views November 8, 2018 UC Davis Health Diabetes and Endocrinology Symposium Stepwise Therapy Versus Initial Combination Therapy in Diabetes FEATURING John Yoon 375 views December 6, 2018 1 UC Davis Health Diabetes and Endocrinology Symposium Mixing and Matching Antidiabetic Medications: What's the Best Combination

It is a versatile antioxidant that plays a vital role in protecting the body and maintaining optimal health.

The expansion will increase the manufacturing capacity of active pharmaceutical ingredients (APIs) for Zepbound and Mounjaro, GLP-1 treatments indicated for obesity and type 2 diabetes

This is not a regulatory recap